PND9 Exploring Serious Adverse Events Associated With Hospitalizations in a Long-term, Phase 3, Open-Label, Repeat-Dose, Safety Study of Diazepam Nasal Spray for Patients With Epilepsy

Authors :: M. Sperling
R.E. Hogan
A.L. Rabinowicz
James W. Wheless
D. Tarquinio
E. Carrazana
N. Fountain
Dennis J. Dlugos
Source :: Value in Health. 24:S159
Publication Year :: 2021
Publisher :: Elsevier BV, 2021.

Subjects :: business.industry
Health Policy
medicine.medical_treatment
Public Health, Environmental and Occupational Health
medicine.disease
Repeat dose
Term (time)
Epilepsy
Nasal spray
Anesthesia
medicine
Open label
business
Adverse effect
Diazepam
medicine.drug

Tools